Lymphoma trial tests which chemo combo works best for younger patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification). * Age from18 to 59 years, eligible for transplant. * Patient not previously treated. * Baseline FDG-PET Scan (PET0) performed before any treatment with at least one hypermetabolic lesion. * Index prognostic factors (IPI) 2 or 3. * With a minimum life expectancy of 3 months. * Negative HIV, HBV and HCV serologies £ 4 weeks (except after vaccination). * Having previously signed a written informed consent. Exclusion Criteria: * Any other histological type of lymphoma. * Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included. * Central nervous system or meningeal involvement by lymphoma. * Contra-indication to any drug contained in the chemotherapy regimens. * Poor renal function (creatinin level \>150 mmol/l), poor hepatic function (total bilirubin level \>30 mmol/l, transaminases \>2.5 maximum normal level) unless these abnormalities are related to the lymphoma. * Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration. * Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ)cervical carcinoma. * Any serious active disease (according to the investigator's decision). * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy. * Pregnant or lactating women or women of childbearing potential not currently practicing an adequate method of contraception * Adult patient under tutelage. * Impossibility to performed a baseline PET scan (PET0) before randomization and treatment beginning